nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2010 | Original Paper

Clinical significance of pAKT and CD44v6 overexpression with breast cancer

verfasst von: Pei Yu, Ling Zhou, Weifeng Ke, Ke Li

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

CD44v6 contributes to apoptosis resistance and metastasis via upregulated activity of the PI3K/AKT pathway. The purpose of this study was to investigate the expression patterns and predictive value of phosphorylated AKT (pAKT) and CD44v6 in breast cancer tissues.

Methods

Expression of pAkt and CD44v6 protein was detected using immunohistochemistry in breast cancer tissues and lymph node tissues in 98 patients. The correlation between the expression of pAkt, CD44v6 and other disease-related characteristics was investigated. The prognostic value of pAKT and CD44v6 overexpression for overall survival (OS) and disease free survival (DFS) was determined.

Results

37 cases (37.8%) were observed as positive for pAkt expression, and 38 cases (38.8%) for CD44V6 overexpression. Staining was positive for pAKT in 20 of 38 (52.6%) CD44v6(+) and 17 of 60 (28.3%) CD44v6(−) (P = 0.016). A progressively increased trend of CD44v6 overexpression was observed from node(−) primary breast cancer tissues to node(+) primary cancer tissues to node(+) lymph tissues (P = 0.000). In univariate analysis lymph node status, pAKT and CD44V6 were significantly associated with a decreased OS and DFS. Multivariate analysis revealed that CD44v6 status was associated with a reduced OS (P = 0.003), and pAKT and CD44v6 with a shorter DFS (P = 0.012 and 0.016, respectively).

Conclusions

Our data suggested that there had an intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. The overexpression of CD44v6 was an independent prognostic marker for predicting OS and DFS of breast cancer patients.

Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988CrossRefPubMed

Andre F, Nahta R, Conforti R et al (2008) Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19(2):315–320CrossRefPubMed

Ayroldi E, Cannarile L, Migliorati G et al (1995) CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 86(7):2672–2678PubMed

Bates RC, Elith CA, Thorne RF et al (1998) Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line. Cell Adhes Commun 6(1):21–38CrossRefPubMed

Berner HS, Suo Z, Risberg B et al (2003) Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42(6):546–554CrossRefPubMed

Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18(4):251–259CrossRefPubMed

Bourguignon LY, Singleton PA, Zhu H et al (2003) Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278(32):29420–29434CrossRefPubMed

Chalhoub N, Baker SJ (2009) PTEN and the PI3-Kinase pathway in Cancer. Annu Rev Pathol 4:127–150CrossRefPubMed

Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88(4):435–437CrossRefPubMed

Friedrichs K, Franke F, Lisboa BW et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22):5424–5433PubMed

Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013–38020CrossRefPubMed

Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24CrossRefPubMed

Gunthert AR, Strater J, von Reyher U et al (1996) Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol 134(4):1089–1096CrossRefPubMed

Herrera-Gayol A, Jothy S (1999) Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 66(2):149–156CrossRefPubMed

Herrlich P, Zoller M, Pals ST et al (1993) CD44 splice variants: metastases meet lymphocytes. Immunol Today 14(8):395–399CrossRefPubMed

Hudson DL, Sleeman J, Watt FM (1995) CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 108(Pt 5):1959–1970PubMed

Jansen RH, Joosten-Achjanie SR, Arends JW et al (1998) CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 9(1):109–111CrossRefPubMed

Janssen EA, Soiland H, Skaland I et al (2007) Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years. Cell Oncol 29(1):25–35PubMed

Jones PF, Jakubowicz T, Hemmings BA (1991) Molecular cloning of a second form of rac protein kinase. Cell Regul 2(12):1001–1009PubMed

Kamikura DM, Khoury H, Maroun C et al (2000) Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3’-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol 20(10):3482–3496CrossRefPubMed

Katso R, Okkenhaug K, Ahmadi K et al (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615–675CrossRefPubMed

Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615–619CrossRefPubMed

Kim Y, Lee YS, Choe J et al (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283(33):22513–22528CrossRefPubMed

Klingbeil P, Marhaba R, Jung T et al (2009) CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 7(2):168–179CrossRefPubMed

Knuefermann C, Lu Y, Liu B et al (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205–3212CrossRefPubMed

Lee JL, Wang MJ, Sudhir PR et al (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67(5):2089–2097CrossRefPubMed

Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11(1):31–44CrossRefPubMed

Ma W, Deng Y, Zhou L (2005) The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol) 17(4):258–263

Marhaba R, Freyschmidt-Paul P, Zoller M (2006) In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol 36(11):3017–3032CrossRefPubMed

Modi S, DiGiovanna MP, Lu Z et al (2005) Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 23(6):483–487CrossRefPubMed

Sarbassov DD, Guertin DA, Ali SM et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101CrossRefPubMed

Schmitz KJ, Otterbach F, Callies R et al (2004) Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17(1):15–21CrossRefPubMed

Stal O, Perez-Tenorio G, Akerberg L et al (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5(2):R37–R44CrossRefPubMed

Subramaniam V, Vincent IR, Gardner H et al (2007) CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 83(2):207–215CrossRefPubMed

Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159(2):431–437PubMed

Tokunaga E, Kataoka A, Kimura Y et al (2006a) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42(5):629–635CrossRefPubMed

Tokunaga E, Kimura Y, Oki E et al (2006b) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118(2):284–289CrossRefPubMed

Tulasne D, Foveau B (2008) The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 15(3):427–434CrossRefPubMed

Wu Y, Mohamed H, Chillar R et al (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10(1):R3CrossRefPubMed

Zhou X, Tan M, Stone Hawthorne V et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779–6788CrossRefPubMed

Titel: Clinical significance of pAKT and CD44v6 overexpression with breast cancer
verfasst von: Pei Yu
Ling Zhou
Weifeng Ke
Ke Li
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0779-x

Springer Medizin

Clinical significance of pAKT and CD44v6 overexpression with breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2010

Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy

Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers

Suppression of human MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs targeting focal adhesion kinase

Potential roles for PA28β in gastric adenocarcinoma development and diagnosis

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie